- WKN: 663200
- ISIN: DE0006632003
- Land: Deutschland
Nachricht vom 20.11.2019 | 22:03
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure (news with additional features)
DGAP-News: MorphoSys AG
/ Key word(s): Personnel
Planegg/Munich, Germany, November 20, 2019
Markus Enzelberger, Chief Scientific Officer of MorphoSys, Announces His Departure
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) today announced that Dr. Markus Enzelberger, the company's Chief Scientific Officer (CSO), has decided to step down as CSO and member of the company's Management Board to explore new opportunities. Dr. Enzelberger will leave MorphoSys on February 29, 2020. Following Dr. Enzelberger's departure, the MorphoSys research organization will be integrated into the Clinical Development segment under the lead of Dr. Malte Peters, Chief Development Officer.
Dr. Enzelberger joined MorphoSys in 2002 and served in various leadership positions within the Company's R&D organization until taking up the position of Senior Vice President Discovery, Alliances and Technologies in 2012. In this position he was responsible for the drug discovery activities for both MorphoSys's proprietary and partnered programs as well as for technology development before being appointed CSO in November 2017.
In accepting Dr. Enzelberger's decision, Dr. Marc Cluzel, Chairman of the Supervisory Board of MorphoSys said, "On behalf of the entire Supervisory Board I would like to extend my deepest gratitude to Markus for his exceptional dedication and loyalty over the past 17 years. MorphoSys today rests on a solid foundation of outstanding science and technology expertise, which was substantially shaped by Markus' long-standing commitment and leadership."
Dr. Jean-Paul Kress, Chief Executive Officer of MorphoSys adds, "It is thanks to our market leadership in antibody technologies that MorphoSys today is able to progress on its successful growth trajectory and to advance the transformation into a commercial-stage company. Although our tenures only briefly overlapped, I would like to acknowledge Markus' vital contribution and the gratitude I and my colleagues of the management board owe him."
"It has been a privilege to be part of the MorphoSys success story and I am immensely proud of how we have been able to build up and leverage our strong research capabilities to grow the organization." says Dr. Enzelberger. "While I'm looking forward to new opportunities to share my knowledge, I am convinced that MorphoSys is in very good hands to achieve the next stage of its evolution into an integrated biopharmaceutical company. I would like to thank the Supervisory Board and all my colleagues for their trust on this exceptional journey."
About Markus Enzelberger
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCERTM are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.
For more information, please contact:
Dr. Sarah Fakih
Document title: Media Release
|Phone:||+49 (0)89 899 27-0|
|Fax:||+49 (0)89 899 27-222|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq|
|EQS News ID:||917489|
|End of News||DGAP News Service|
Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet
Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.
Der AKTIONÄR News
23. September 20:30 Schlussglocke: Sell-off an der Wall Street – Apple zieht Dow Jones ...
23. September 20:00 Überraschung: 5 Thesen, 8 Aktien mit maximalem OHO-Effekt
23. September 19:50 Zoom: Diese Aktie ist unglaublich!
23. September 18:55 Wall Street tiefrot: Apple, Amazon, Tesla und Co ziehen die Märkte ...
23. September 18:40 Nächstes Tesla-Opfer: Albemarle
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
23. September 2020